ID   BS153-ResE
AC   CVCL_B3PI
SY   BS153ResE
DR   Wikidata; Q110432644
RX   PubMed=23877316;
CC   Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_S444 ! BS153
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 16-12-21; Last updated: 29-06-23; Version: 4
//
RX   PubMed=23877316; DOI=10.1093/neuonc/not093; PMCID=PMC3779041;
RA   Schulte A., Liffers K., Kathagen-Buhmann A., Riethdorf S., Zapf S.,
RA   Merlo A., Kolbe K., Westphal M., Lamszus K.;
RT   "Erlotinib resistance in EGFR-amplified glioblastoma cells is
RT   associated with upregulation of EGFRvIII and PI3Kp110delta.";
RL   Neuro-oncol. 15:1289-1301(2013).
//